Skip header and navigation

Refine By

279 records – page 1 of 28.

A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults.

https://arctichealth.org/en/permalink/ahliterature56626
Source
Scand J Infect Dis. 2002;34(8):610-4
Publication Type
Article
Date
2002
Author
K. Levie
I. Gjorup
P. Skinhøj
M. Stoffel
Source
Scand J Infect Dis. 2002;34(8):610-4
Date
2002
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Belgium
Comparative Study
Denmark
Dose-Response Relationship, Drug
Female
Hepatitis B - prevention & control
Hepatitis B Antibodies - analysis
Hepatitis B Surface Antigens - analysis
Hepatitis B vaccines - administration & dosage
Humans
Immunity - physiology
Immunization - methods
Immunization Schedule
Male
Reference Values
Research Support, Non-U.S. Gov't
Sensitivity and specificity
Single-Blind Method
Vaccines, Synthetic - administration & dosage
Abstract
An open-label randomized study was undertaken to compare a 2-dose regimen (Months 0 and 6) of hepatitis B surface antigen (HBsAg) vaccine formulated with a novel adjuvant (HBsAg/AS04) with a standard 3-dose regimen (Months 0, 1 and 6) of licensed recombinant HBsAg vaccine in terms of immunogenicity and reactogenicity when administered to healthy subjects aged between 15 and 40 y. At 1 and 6 months after the full vaccination course there was a 100% seroprotection rate (anti-HBs > or = 10 mIU/ml) with the HBsAg/AS04 vaccine, compared with a 99% response rate with the licensed vaccine. The corresponding geometric mean titres were significantly higher for the novel vaccine compared to the standard vaccine: 15,468 and 2,745 mIU/ml at Months 7 and 12 vs. 6,274 and 1,883 mIU/ml, respectively. There was a higher prevalence of local symptoms with the adjuvant vaccine (90% of doses) than with the standard vaccine (48% of doses). However, these symptoms (pain, swelling and redness) were predominantly of mild-to-moderate intensity and resolved rapidly without treatment. A 2-dose regimen of the new HBsAg/AS04 adjuvant vaccine therefore compared favourably to the standard regimen in healthy young adults. It is anticipated that the simplified vaccination schedule may improve compliance and reduce costs.
PubMed ID
12238579 View in PubMed
Less detail

Abdominal symptoms and cancer in the abdomen: prospective cohort study in European primary care.

https://arctichealth.org/en/permalink/ahliterature303030
Source
Br J Gen Pract. 2018 05; 68(670):e301-e310
Publication Type
Journal Article
Date
05-2018
Author
Knut Holtedahl
Peter Hjertholm
Lars Borgquist
Gé A Donker
Frank Buntinx
David Weller
Tonje Braaten
Jörgen Månsson
Eva Lena Strandberg
Christine Campbell
Joke C Korevaar
Ranjan Parajuli
Author Affiliation
Department of Community Medicine, UiT The Arctic University of Norway, Norway.
Source
Br J Gen Pract. 2018 05; 68(670):e301-e310
Date
05-2018
Language
English
Publication Type
Journal Article
Keywords
Abdominal Neoplasms - diagnosis - epidemiology - pathology
Abdominal Pain - etiology - pathology
Adolescent
Adult
Aged
Aged, 80 and over
Belgium - epidemiology
Denmark - epidemiology
Early Detection of Cancer
Female
Gastrointestinal Hemorrhage - etiology - pathology
Hematuria - etiology - pathology
Humans
Male
Middle Aged
Netherlands - epidemiology
Norway - epidemiology
Primary Health Care
Prospective Studies
Referral and Consultation
Scotland - epidemiology
Sweden - epidemiology
Weight Loss
Young Adult
Abstract
Different abdominal symptoms may signal cancer, but their role is unclear.
To examine associations between abdominal symptoms and subsequent cancer diagnosed in the abdominal region.
Prospective cohort study comprising 493 GPs from surgeries in Norway, Denmark, Sweden, Scotland, Belgium, and the Netherlands.
Over a 10-day period, the GPs recorded consecutive consultations and noted: patients who presented with abdominal symptoms pre-specified on the registration form; additional data on non-specific symptoms; and features of the consultation. Eight months later, data on all cancer diagnoses among all study patients in the participating general practices were requested from the GPs.
Consultations with 61 802 patients were recorded and abdominal symptoms were documented in 6264 (10.1%) patients. Malignancy, both abdominal and non-abdominal, was subsequently diagnosed in 511 patients (0.8%). Among patients with a new cancer in the abdomen (n = 251), 175 (69.7%) were diagnosed within 180 days after consultation. In a multivariate model, the highest sex- and age-adjusted hazard ratio (HR) was for the single symptom of rectal bleeding (HR 19.1, 95% confidence interval = 8.7 to 41.7). Positive predictive values of >3% were found for macroscopic haematuria, rectal bleeding, and involuntary weight loss, with variations according to age and sex. The three symptoms relating to irregular bleeding had particularly high specificity in terms of colorectal, uterine, and bladder cancer.
A patient with undiagnosed cancer may present with symptoms or no symptoms. Irregular bleeding must always be explained. Abdominal pain occurs with all types of abdominal cancer and several symptoms may signal colorectal cancer. The findings are important as they influence how GPs think and act, and how they can contribute to an earlier diagnosis of cancer.
PubMed ID
29632003 View in PubMed
Less detail

Abdominal symptoms and cancer in the abdomen: prospective cohort study in European primary care.

https://arctichealth.org/en/permalink/ahliterature303215
Source
Br J Gen Pract. 2018 05; 68(670):e301-e310
Publication Type
Journal Article
Date
05-2018
Author
Knut Holtedahl
Peter Hjertholm
Lars Borgquist
Gé A Donker
Frank Buntinx
David Weller
Tonje Braaten
Jörgen Månsson
Eva Lena Strandberg
Christine Campbell
Joke C Korevaar
Ranjan Parajuli
Author Affiliation
Department of Community Medicine, UiT The Arctic University of Norway, Norway.
Source
Br J Gen Pract. 2018 05; 68(670):e301-e310
Date
05-2018
Language
English
Publication Type
Journal Article
Keywords
Abdominal Neoplasms - diagnosis - epidemiology - pathology
Abdominal Pain - etiology - pathology
Adolescent
Adult
Aged
Aged, 80 and over
Belgium - epidemiology
Denmark - epidemiology
Early Detection of Cancer
Female
Gastrointestinal Hemorrhage - etiology - pathology
Hematuria - etiology - pathology
Humans
Male
Middle Aged
Netherlands - epidemiology
Norway - epidemiology
Primary Health Care
Prospective Studies
Referral and Consultation
Scotland - epidemiology
Sweden - epidemiology
Weight Loss
Young Adult
Abstract
Different abdominal symptoms may signal cancer, but their role is unclear.
To examine associations between abdominal symptoms and subsequent cancer diagnosed in the abdominal region.
Prospective cohort study comprising 493 GPs from surgeries in Norway, Denmark, Sweden, Scotland, Belgium, and the Netherlands.
Over a 10-day period, the GPs recorded consecutive consultations and noted: patients who presented with abdominal symptoms pre-specified on the registration form; additional data on non-specific symptoms; and features of the consultation. Eight months later, data on all cancer diagnoses among all study patients in the participating general practices were requested from the GPs.
Consultations with 61 802 patients were recorded and abdominal symptoms were documented in 6264 (10.1%) patients. Malignancy, both abdominal and non-abdominal, was subsequently diagnosed in 511 patients (0.8%). Among patients with a new cancer in the abdomen (n = 251), 175 (69.7%) were diagnosed within 180 days after consultation. In a multivariate model, the highest sex- and age-adjusted hazard ratio (HR) was for the single symptom of rectal bleeding (HR 19.1, 95% confidence interval = 8.7 to 41.7). Positive predictive values of >3% were found for macroscopic haematuria, rectal bleeding, and involuntary weight loss, with variations according to age and sex. The three symptoms relating to irregular bleeding had particularly high specificity in terms of colorectal, uterine, and bladder cancer.
A patient with undiagnosed cancer may present with symptoms or no symptoms. Irregular bleeding must always be explained. Abdominal pain occurs with all types of abdominal cancer and several symptoms may signal colorectal cancer. The findings are important as they influence how GPs think and act, and how they can contribute to an earlier diagnosis of cancer.
PubMed ID
29632003 View in PubMed
Less detail

[ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?].

https://arctichealth.org/en/permalink/ahliterature164781
Source
Rev Med Liege. 2007 Jan;62(1):48-52
Publication Type
Article
Date
Jan-2007
Author
A J Scheen
Author Affiliation
Université de Liège, Belgique.
Source
Rev Med Liege. 2007 Jan;62(1):48-52
Date
Jan-2007
Language
French
Publication Type
Article
Keywords
Administration, Oral
Belgium
Canada
Cost-Benefit Analysis
Diabetes Mellitus, Type 2 - drug therapy - economics
Double-Blind Method
European Union
Glyburide - therapeutic use
Humans
Hypoglycemic agents - therapeutic use
Metformin - therapeutic use
Middle Aged
Quality of Life
Thiazolidinediones - therapeutic use
Treatment Outcome
United States
Abstract
ADOPT ("A Diabetes Outcome Progression Trial") is a double-blind, controlled clinical trial that aims at assessing the efficacy of rosiglitazone, as compared to metformin or glibenclamide, in maintaining long-term glycaemic control in patients with recently diagnosed type 2 diabetes. It randomized 4,360 patients who were followed for a median of 4.0 years. The cumulative incidence of monotherapy failure (defined as a confirmed level of fasting plasma glucose level of more than 180 mg/dl) averaged at 5 years 15% with rosiglitazone, 21% with metformin, and 34% with glibenclamide. This represents a risk reduction for rosiglitazone of 32% as compared to metformin and 63% as compared to glibenclamide (P
PubMed ID
17343130 View in PubMed
Less detail

[AIDS and drug addicts in the view of an epidemiologist]

https://arctichealth.org/en/permalink/ahliterature8724
Source
AIDS Forsch. 1987 Jun;(6):323-34
Publication Type
Article
Date
Jun-1987
Author
B. Velimirovic
Source
AIDS Forsch. 1987 Jun;(6):323-34
Date
Jun-1987
Language
German
Publication Type
Article
Keywords
Acquired Immunodeficiency Syndrome
Asia
Asia, Western
Austria
Behavior
Belgium
Denmark
Developed Countries
Disease
English Abstract
Europe
Germany, West
Great Britain
Greece
HIV Infections
Ireland
Israel
Italy
Malta
Netherlands
Norway
Pharmaceutical Preparations
Portugal
Scandinavia
Sexual Behavior
Social Problems
Spain
Substance-Related Disorders
Sweden
Switzerland
Therapeutics
Virus Diseases
Abstract
Data from 12 different European countries show a rapid increase in HIV antibody positivity among drug users or a high degree of contamination already reached wherever studies have been made. Until 31 December 1986, 698 (18%) of AIDS cases were among drug users, of which 600 (15%) of AIDS cases were solely drug users, and 98 (3%) were in addition homosexual or bisexual. A further increase is expected. Because of the epidemiological importance for transmission to the heterosexual population, this problem has become a focus of attention. Drug abusing prostitutes constitute a major source of infection for the heterosexual population and newborns. The increase in the number of AIDS cases in 1986 among male drug abusers was 98 - that is up 61% compared to previous years; among women, the increase was 56%. The 3 main approaches to solution of this problem, i.e. interdiction of the drug trade, availability of sterile needles, and an education program have not proven as successful as anticipated. Relevant indications of the progress of infection in society can only be obtained by systematic observation of conversion rates in differential subgroups, i.e. drug abusers, newly incarcerated drug abusers, male and female prostitutes who use drugs, and individuals newly reporting for treatment. Separation of HIV antibody positives and negatives in therapeutic communities which are not drug free is recommended for epidemiological purposes in view of the developments to date. Nor should forced segregation of the infected from noninfected be dismissed out of hand.
PubMed ID
12281241 View in PubMed
Less detail

Alloscardovia omnicolens gen. nov., sp. nov., from human clinical samples.

https://arctichealth.org/en/permalink/ahliterature162515
Source
Int J Syst Evol Microbiol. 2007 Jul;57(Pt 7):1442-6
Publication Type
Article
Date
Jul-2007
Author
Geert Huys
Marc Vancanneyt
Klaas D'Haene
Enevold Falsen
Georges Wauters
Peter Vandamme
Author Affiliation
Laboratory of Microbiology, Ghent University, K. L. Ledeganckstraat 35, B-9000 Ghent, Belgium. geert.huys@UGent.be
Source
Int J Syst Evol Microbiol. 2007 Jul;57(Pt 7):1442-6
Date
Jul-2007
Language
English
Publication Type
Article
Keywords
Actinobacteria - classification - genetics - isolation & purification - metabolism
Aerobiosis
Bacterial Proteins - genetics
Bacterial Typing Techniques
Base Composition
Belgium
Chaperonin 60 - genetics
Cluster analysis
DNA Fingerprinting
DNA, Bacterial - chemistry - genetics
DNA, Ribosomal - chemistry - genetics
Fermentation
Genes, rRNA
Genotype
Gram-Positive Bacterial Infections - microbiology
Humans
Molecular Sequence Data
Norway
Nucleic Acid Hybridization
Phylogeny
Polymerase Chain Reaction
RNA, Bacterial - genetics
RNA, Ribosomal, 16S - genetics
Sequence Analysis, DNA
Sequence Homology, Nucleic Acid
Sweden
Abstract
The taxonomic position of 12 isolates tentatively assigned to the genus Bifidobacterium on the basis of a limited phenotypic characterization was examined. The isolates were collected between 1978 and 2005 in Belgium, Sweden and Norway, and originated from various human clinical samples, including urine, blood, urethra, oral cavity, tonsil, and abscesses of lung and aortic valve. On the basis of band number and clustering analysis, repetitive DNA element-based PCR fingerprinting using the BOXA1R and (GTG)(5) primers indicated that the clinical isolates represented a taxon probably not belonging to the genus Bifidobacterium. Analysis of 16S rRNA gene sequence similarities revealed that the isolates were most closely affiliated to Parascardovia denticolens LMG 18312(T) (93.0-93.2 %), Scardovia inopinata LMG 18313(T) (92.9-93.1 %) and other members of the Bifidobacteriaceae, indicating that the isolates belong to a novel genus within that family. This observation was further substantiated by the results of partial sequencing of the heat-shock protein 60 gene (hsp60) and determination of the DNA G+C contents (47.3-48.3 mol%). Members of the novel taxon can be phenotypically distinguished from S. inopinata, P. denticolens and Gardnerella vaginalis by the ability to grow on agar under aerobic conditions and on the basis of positive reactions for acid production from L-arabinose, raffinose, salicin and D-xylose. Unambiguous phenotypic differentiation from Aeriscardovia aeriphila and Bifidobacterium species may be difficult, so phenotypic analyses should be complemented by molecular methods. The values for DNA-DNA binding among four members of the novel genus were in the range of 89-100 %, indicating that the strains should be considered as a single novel species of a novel genus, for which the name Alloscardovia omnicolens gen. nov., sp. nov. is proposed. The type strain of Alloscardovia omnicolens is CCUG 31649(T) (=LMG 23792(T)).
PubMed ID
17625172 View in PubMed
Less detail

An outbreak of diarrhoeic shellfish poisoning in Antwerp, Belgium.

https://arctichealth.org/en/permalink/ahliterature31065
Source
Euro Surveill. 2002 Oct;7(10):138-41
Publication Type
Article
Date
Oct-2002
Author
K. De Schrijver
I. Maes
L. De Man
J. Michelet
Author Affiliation
Gezondheidsinspectie Copernicuslaan 1 Antwerpen, Belgium.
Source
Euro Surveill. 2002 Oct;7(10):138-41
Date
Oct-2002
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Age Distribution
Aged
Aged, 80 and over
Belgium - epidemiology
Child
Child, Preschool
Comorbidity
Diarrhea - epidemiology
Disease Outbreaks - statistics & numerical data
Feces - microbiology
Food Poisoning - diagnosis - epidemiology
Humans
Middle Aged
Okadaic Acid - analysis
Protozoan Infections - diagnosis - epidemiology
Shellfish - microbiology - poisoning
Abstract
In Antwerp, Belgium, 403 cases of diarrhoeic shellfish poisoning were reported after consumption of blue mussels. Symptoms included diarrhoea, vomiting, abdominal pain, and nausea. The analysis of faecal specimens from patients allowed diagnosis exclusions for bacteria and viruses. Mouse-assays revealed the presence of biotoxins specific of dinoflagellates, which were identified and quantified by LC-MS. The mussels were imported from Denmark, and were part of a batch presenting high concentrations of okadaic acid above the regulatory limits.
PubMed ID
12631993 View in PubMed
Less detail

279 records – page 1 of 28.